Top Cannabis Plays-THC Therapeutics, Inc

HENDERSON, NV / ACCESSWIRE / March 12, 2019 / Year to date, the Global Cannabis Stock Index is up almost 50% in less than three months. It's safe to say investors are bullish on the cannabis. Here are a few stocks to research if you're looking to invest in cannabis.

Due to the cannabis index's strong performance, some more well-known companies in the industry may have limited short-term upside. We found a relatively under the radar company worth researching now, THC Therapeutics, Inc. (THCT). The company said the US patent office has accepted ALL 20 claims for their herb dryer The dHydronator, which can reduce moisture content of Cannabis to 10% in only 10-14 hours. The dHydronator® also destroys harmful surface contaminants & pathogens. This company is worth a look for cannabis investors just learning about THCT.

Today we are highlighting: THC Therapeutics, Inc. (THCT), Zynerba Pharmaceuticals (ZYNE), Cara Therapeutics, Inc. (CARA), India Globalization Capital, Inc. (IGC), and GW Pharmaceuticals plc (GWPH).

THC Therapeutics, Inc. (THCT) (Market Cap: $92.627M; Share Price: $7.04) has developed a sanitizing herb dryer, The dHydronator®, their laboratory-proven product is specifically designed for drying and sanitizing freshly harvested Cannabis and herbs. THCT's product has been tested by two independent laboratories, testing covered over 6 strains and 9 independent tests to confirm the findings.

As we mentioned earlier, the US patent office has accepted ALL 20 claims for The dHydronator®, this is big. Start your research today.

_______

Zynerba Pharmaceuticals (ZYNE) (Market Cap: $85.667M; Share Price: $4.86) reported a loss of $7.8 million in its fourth quarter. The Devon, Pennsylvania-based company said it had a loss of 44 cents per share. VF The specialty pharmaceutical company posted revenue of $86,000 in the period. For the year, the company reported that its loss widened to $39.9 million, or $2.61 per share. Revenue was reported as $86,000.

_______

Cara Therapeutics, Inc. (CARA) (Market Cap: $675.724M; Share Price: $17.13) announced that the Company will host a conference call and live audio webcast on Tuesday, March 12, 2019, at 4:30 p.m. ET to report fourth quarter and full year 2018 financial results and provide a corporate update.

_______

India Globalization Capital, Inc. (IGC) (Market Cap: $95.404M; Share Price: $2.41) announced earlier this month that the Company had successfully challenged NYSE American's decision to delist the common stock of the Company from trading on the Exchange under the Exchange's appeal procedures. In a written decision issued on February 20, 2019, a review panel of the Exchange unanimously ruled to set aside the Exchange's October 29, 2018 decision to delist the Company's common stock, finding that the Company has not discontinued the business it conducted at the time it was first listed on the Exchange.

_______

GW Pharmaceuticals plc (GWPH) (Market Cap: $5.176B; Share Price: $169.29) reported impressive numbers highlighted by its strong launch for cannabinoid oil Epidiolex in seizure treatment. Epidiolex generated $4.7 million in sales over two months.

Legal Disclaimer:

This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to a three-month term consulting agreement with THCT dated 2/14/18. The agreement calls for 50,000 restricted shares of THCT per month. All payments were made directly by THC Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. THCT was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.